New pharmacotherapy options for multiple myeloma (Q38673764)

5 September 2017

New pharmacotherapy options for multiple myeloma (English)

1 reference

5 September 2017

0 references

5

Antonio Palumbo

1 reference

5 September 2017

Roberto Mina

1

1 reference

5 September 2017

Chiara Cerrato

series ordinal

2

1 reference

5 September 2017

Annalisa Bernardini

series ordinal

3

1 reference

5 September 2017

Elena Aghemo

series ordinal

4

1 reference

5 September 2017

language of work or name

English

0 references

publication date

18 December 2015

1 reference

Expert Opinion on Pharmacotherapy

5 September 2017

1 reference

5 September 2017

17

1 reference

5 September 2017

2

1 reference

5 September 2017

181-192

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

5 September 2017

1 reference

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Recent major improvement in long-term survival of younger patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Autologous transplantation and maintenance therapy in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Lenalidomide after stem-cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Development of the proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Epoxomicin, a new antitumor agent of microbial origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Targeted therapies in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Combination immune therapies to enhance anti-tumor responses by NK cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Oral therapy for multiple myeloma: ixazomib arriving soon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1115016

10.1517/14656566.2016.1115016

21 January 2018

Identifiers

DOI

1 reference

5 September 2017

1 reference